骨粗鬆症の疫学予測(~2028)

◆英語タイトル:Osteoporosis Epidemiology Forecast to 2028
◆商品コード:DATA00109018
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2019年12月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD3,250 ⇒換算¥370,500見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD9,750 ⇒換算¥1,111,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Osteoporosis Epidemiology Forecast to 2028
DelveInsight’s ‘Osteoporosis—Epidemiology Forecast to 2028’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Osteoporosis in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2028

Osteoporosis Epidemiology

The Osteoporosis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Osteoporosis are studied through all possible division to give a better understanding of the Disease scenario in the 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Osteoporosis Epidemiology Segmentation

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
The disease epidemiology covered in the report is segmented by:
• Prevalence of Osteoporosis
• Diagnosed Prevalent Population of Osteoporosis
• Gender-specific Prevalence of Osteoporosis
• Prevalence of Primary Osteoporosis
• Prevalence of Secondary Osteoporosis
• Incidence of Osteoporotic Fractures
• Osteoporosis-related comorbidities
According to DelveInsight, the total diagnosed prevalent population of Osteoporosis in the seven major markets were 28,097,783 cases in 2017. Moreover, the total diagnosed prevalent population of Osteoporosis in the US were 6,380,754 cases in 2017.

Report Scope

• The report covers the detailed overview of Osteoporosis explaining its causes, symptoms, pathophysiology, diagnostic biomarkers, differential diagnosis, diagnosis and treatment patterns.
• The report provides insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Osteoporosis.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology by type-specific cases, comorbidities-related cases, and osteoporotic fracture related cases of Osteoporosis in the 7MM.

Key strengths

• 10-Year Forecast of Osteoporosis epidemiology
• 7MM Coverage
• Total Prevalent Cases of Osteoporosis
• Prevalent Cases according to segmentation

Key assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Note: We understand the needs of the rapidly changing market and DelveInsight’s is helping the clients by providing them with the most up to date Report. It usually takes 5–7 days

【レポートの目次】

1. Key Insights
2. Disease Background and Overview: Osteoporosis
2.1. Introduction
2.2. Types of osteoporosis
2.2.1. Primary osteoporosis
2.2.2. Secondary Osteoporosis
2.2.3. Glucocorticoid-Induced Osteoporosis
2.3. Causes of Osteoporosis
2.4. Symptoms
2.5. Pathophysiology of Osteoporosis
2.5.1. Architectural composition: cortical versus cancellous bone
2.5.2. Molecular composition: mineralized versus nonmineralized components
2.5.3. Cellular control of bone mass: osteoblasts and osteoclasts
2.5.4. Circulating factors that influence bone cell function
2.5.5. Age-related bone loss and osteoporosis
2.5.6. Geometry: effects of osteoporosis on cancellous bone
2.5.7. Geometry: effects of osteoporosis on cortical bone
2.5.8. Geometry: effects on vertebral body strength
2.6. Pathology of Osteoporosis
2.6.1. Factors That Affect Bone Quantity and Quality
2.6.2. Bone Remodeling and its Relationship to Bone Quantity
2.7. Risk Factors for Osteoporosis
2.8. Diagnosis of osteoporosis
2.8.1. Fracture Risk Assessment Tool Model (FRAX)
2.8.2. Vertebral imaging (Vertebral fracture assessment)
2.8.3. Biochemical bone turnover marker (BTM)
2.8.4. Dual-Energy X-Ray Absorptiometry (DXA)
2.8.5. Quantitative Ultrasound (QUS)
2.8.6. Quantitative Computed Tomography (QCT) and Peripheral QCT (pQCT)
2.8.7. Quality of DXA AND VFA
2.9. Diagnostic Biomarkers of Osteoporosis
2.9.1. miR-21 and miR-148a
2.9.2. miR-31 and miR-194
2.9.3. miR-133a and miR-27
2.9.4. miR-30b and miR-142
2.10. Differential diagnosis
2.11. Diagnostic Algorithm
2.12. European Guidelines for diagnosis of Osteoporosis in postmenopausal women
2.12.1. Diagnosis of osteoporosis
2.12.2. Assessment of fracture risk
2.13. Diagnostic guidelines from the Italian Society for Orthopedics and Traumatology
2.13.1. Diagnosis of osteoporosis
3. Recognized Establishments
3.1.1. United States
3.1.2. Europe
3.1.3. Japan
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Countries Total Diagnosed Incident Patient Population of Osteoporosis
5. Country Wise-Epidemiology of Osteoporosis
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Osteoporosis Prevalence in the United States
5.1.3. Osteoporosis Diagnosed Prevalent Population in the United States
5.1.4. Osteoporosis Gender-specific Prevalence in the United States
5.1.5. Primary Osteoporosis Prevalence in the United States
5.1.6. Secondary Osteoporosis Prevalence in the United States
5.1.7. Osteoporotic Fractures Incidence in the United States
5.1.8. Osteoporosis-related comorbidities in the United States
5.2. EU5 Countries
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.3. France
5.2.4. Italy
5.2.5. Spain
5.2.6. United Kingdom
5.3. Germany
5.3.1. Osteoporosis Prevalence in Germany
5.3.2. Osteoporosis Diagnosed Prevalent Population in Germany
5.3.3. Osteoporosis Gender-specific Prevalence in Germany
5.3.4. Primary Osteoporosis Prevalence in Germany
5.3.5. Secondary Osteoporosis Prevalence in Germany
5.3.6. Osteoporotic Fractures Incidence in Germany
5.3.7. Osteoporosis-related comorbidities in Germany
5.4. France
5.4.1. Osteoporosis Prevalence in France
5.4.2. Osteoporosis Diagnosed Prevalent Population in France
5.4.3. Osteoporosis Gender-specific Prevalence in France
5.4.4. Primary Osteoporosis Prevalence in France
5.4.5. Secondary Osteoporosis Prevalence in France
5.4.6. Osteoporotic Fractures Incidence in France
5.4.7. Osteoporosis-related comorbidities in France
5.5. Italy
5.5.1. Osteoporosis Prevalence in Italy
5.5.2. Osteoporosis Diagnosed Prevalent Population in Italy
5.5.3. Osteoporosis Gender-specific Prevalence in Italy
5.5.4. Primary Osteoporosis Prevalence in Italy
5.5.5. Secondary Osteoporosis Prevalence in Italy
5.5.6. Osteoporotic Fractures Incidence in Italy
5.5.7. Osteoporosis-related comorbidities in Italy
5.6. Spain
5.6.1. Osteoporosis Prevalence in Spain
5.6.2. Osteoporosis Diagnosed Prevalent Population in Spain
5.6.3. Osteoporosis Gender-specific Prevalence in Spain
5.6.4. Primary Osteoporosis Prevalence in Spain
5.6.5. Secondary Osteoporosis Prevalence in Spain
5.6.6. Osteoporotic Fractures Incidence in Spain
5.6.7. Osteoporosis-related comorbidities in Spain
5.7. United Kingdom
5.7.1. Osteoporosis Prevalence in the United Kingdom
5.7.2. Osteoporosis Diagnosed Prevalent Population in the United Kingdom
5.7.3. Osteoporosis Gender-specific Prevalence in the United Kingdom
5.7.4. Primary Osteoporosis Prevalence in the United Kingdom
5.7.5. Secondary Osteoporosis Prevalence in the United Kingdom
5.7.6. Osteoporotic Fractures Incidence in the United Kingdom
5.7.7. Osteoporosis-related comorbidities in the United Kingdom
5.8. Japan
5.8.1. Assumptions and Rationale
5.8.2. Osteoporosis Prevalence in Japan
5.8.3. Osteoporosis Diagnosed Prevalent Population in Japan
5.8.4. Osteoporosis Gender-specific Prevalence in Japan
5.8.5. Primary Osteoporosis Prevalence in Japan
5.8.6. Secondary Osteoporosis Prevalence in Japan
5.8.7. Osteoporotic Fractures Incidence in Japan
5.8.8. Osteoporosis-related comorbidities in Japan
6. Appendix
6.1. Report Methodology
7. DelveInsight Capabilities
8. Disclaimer
9. About DelveInsight
Table 1: WHO definitions of osteoporosis based on BMD
Table 2: Differential Diagnosis
Table 3: Total Diagnosed Prevalent Population of Osteoporosis in the 7MM Countries (2017–2028)
Table 4: Osteoporosis Prevalence in the United States (2017–2028)
Table 5: Osteoporosis Diagnosed Prevalent Population in the United States (2017–2028)
Table 6: Osteoporosis Gender-specific Prevalence in the United States (2017–2028)
Table 7: Primary Osteoporosis Prevalence in the United States (2017–2028)
Table 8: Secondary Osteoporosis Prevalence in the United States (2017–2028)
Table 9: Osteoporotic Fractures Incidence in the United States (2017–2028)
Table 10: Osteoporosis-related comorbidities in the United States (2017–2028)
Table 11: Osteoporosis Prevalence in Germany (2017–2028)
Table 12: Osteoporosis Diagnosed Prevalent Population in Germany (2017–2028)
Table 13: Osteoporosis Gender-specific Prevalence in Germany (2017–2028)
Table 14: Primary Osteoporosis Prevalence in Germany (2017–2028)
Table 15: Secondary Osteoporosis Prevalence in Germany (2017–2028)
Table 16: Osteoporotic Fractures Incidence in Germany (2017–2028)
Table 17: Osteoporosis-related comorbidities in Germany (2017–2028)
Table 18: Osteoporosis Prevalence in France (2017–2028)
Table 19: Osteoporosis Diagnosed Prevalent Population in France (2017–2028)
Table 20: Osteoporosis Gender-specific Prevalence in France (2017–2028)
Table 21: Primary Osteoporosis Prevalence in France (2017–2028)
Table 22: Secondary Osteoporosis Prevalence in France (2017–2028)
Table 23: Osteoporotic Fractures Incidence in France (2017–2028)
Table 24: Osteoporosis-related comorbidities in France (2017–2028)
Table 25: Osteoporosis Prevalence in Italy (2017–2028)
Table 26: Osteoporosis Diagnosed Prevalent Population in Italy (2017–2028)
Table 27: Osteoporosis Gender-specific Prevalence in Italy (2017–2028)
Table 28: Primary Osteoporosis Prevalence in Italy (2017–2028)
Table 29: Secondary Osteoporosis Prevalence in Italy (2017–2028)
Table 30: Osteoporotic Fractures Incidence in Italy (2017–2028)
Table 31: Osteoporosis-related comorbidities in Italy (2017–2028)
Table 32: Osteoporosis Prevalence in Spain (2017–2028)
Table 33: Osteoporosis Diagnosed Prevalent Population in Spain (2017–2028)
Table 34: Osteoporosis Gender-specific Prevalence in Spain (2017–2028)
Table 35: Primary Osteoporosis Prevalence in Spain (2017–2028)
Table 36: Secondary Osteoporosis Prevalence in Spain (2017–2028)
Table 37: Osteoporotic Fractures Incidence in Spain (2017–2028)
Table 38: Osteoporosis-related comorbidities in Spain (2017–2028)
Table 39: Osteoporosis Prevalence in the United Kingdom (2017–2028)
Table 40: Osteoporosis Diagnosed Prevalent Population in the United Kingdom (2017–2028)
Table 41: Osteoporosis Gender-specific Prevalence in the United Kingdom (2017–2028)
Table 42: Primary Osteoporosis Prevalence in the United Kingdom (2017–2028)
Table 43: Secondary Osteoporosis Prevalence in the United Kingdom (2017–2028)
Table 44: Osteoporotic Fractures Incidence in the United Kingdom (2017–2028)
Table 45 Osteoporosis-related comorbidities in the United Kingdom (2017–2028)
Table 46: Osteoporosis Prevalence in Japan (2017–2028)
Table 47: Osteoporosis Diagnosed Prevalent Population in Japan (2017–2028)
Table 48: Osteoporosis Gender-specific Prevalence in Japan (2017–2028)
Table 49: Primary Osteoporosis Prevalence in Japan (2017–2028)
Table 50: Secondary Osteoporosis Prevalence in Japan (2017–2028)
Table 51: Osteoporotic Fractures Incidence in Japan (2017–2028)
Table 52: Osteoporosis-related comorbidities in Japan (2017–2028)
Figure 1: Normal bone vs. osteoporotic bone
Figure 2: Overview of the mechanisms of glucocorticoid-induced osteoporosis (GCOP).
Figure 3: Causes of osteoporosis
Figure 4: Symptoms of osteoporosis
Figure 5: Normal bone showing good connectivity as compared to osteoporotic bone showing poor conductivity.
Figure 6: Basic types of stresses that the bone endures
Figure 7: The pathogenesis of osteoporosis-related fractures
Figure 8: The bone remodeling cycle.
Figure 9: Suggested role of FRAX in the assessment of fracture risk
Figure 10: Circulating miRNAs differentially expressed in osteoporotic patients, either upregulated (roman) or downregulated (italic), and their functions studied in bone cells.
Figure 11: Suggested algorithm for diagnosis and management of postmenopausal osteoporosis.
Figure 12: Total Diagnosed Prevalent Patient Population of Osteoporosis in the 7MM Countries (2017–2028)
Figure 13: Osteoporosis Prevalence in the United States (2017–2028)
Figure 14: Osteoporosis Diagnosed Prevalent Population in the United States (2017–2028)
Figure 15: Osteoporosis Gender-specific Prevalence in the United States (2017–2028)
Figure 16: Primary Osteoporosis Prevalence in the United States (2017–2028)
Figure 17: Secondary Osteoporosis Prevalence in the United States (2017–2028)
Figure 18: Osteoporotic Fractures Incidence in the United States (2017–2028)
Figure 19: Osteoporosis-related comorbidities in the United States (2017–2028)
Figure 20: Osteoporosis Prevalence in Germany (2017–2028)
Figure 21: Osteoporosis Diagnosed Prevalent Population in Germany (2017–2028)
Figure 22: Osteoporosis Gender-specific Prevalence in Germany (2017–2028)
Figure 23: Primary Osteoporosis Prevalence in Germany (2017–2028)
Figure 24: Secondary Osteoporosis Prevalence in Germany (2017–2028)
Figure 25: Osteoporotic Fractures Incidence in Germany (2017–2028)
Figure 26: Osteoporosis-related comorbidities in Germany (2017–2028)
Figure 27: Osteoporosis Prevalence in France (2017–2028)
Figure 28: Osteoporosis Diagnosed Prevalent Population in France (2017–2028)
Figure 29: Osteoporosis Gender-specific Prevalence in France (2017–2028)
Figure 30: Primary Osteoporosis Prevalence in France (2017–2028)
Figure 31: Secondary Osteoporosis Prevalence in France (2017–2028)
Figure 32: Osteoporotic Fractures Incidence in France (2017–2028)
Figure 33: Osteoporosis-related comorbidities in France (2017–2028)
Figure 34: Osteoporosis Prevalence in Italy (2017–2028)
Figure 35: Osteoporosis Diagnosed Prevalent Population in Italy (2017–2028)
Figure 36: Osteoporosis Gender-specific Prevalence in Italy (2017–2028)
Figure 37: Primary Osteoporosis Prevalence in Italy (2017–2028)
Figure 38: Secondary Osteoporosis Prevalence in Italy (2017–2028)
Figure 39: Osteoporotic Fractures Incidence in Italy (2017–2028)
Figure 40: Osteoporosis-related comorbidities in Italy (2017–2028)
Figure 41: Osteoporosis Prevalence in Spain (2017–2028)
Figure 42: Osteoporosis Diagnosed Prevalent Population in Spain (2017–2028)
Figure 43: Osteoporosis Gender-specific Prevalence in Spain (2017–2028)
Figure 44: Primary Osteoporosis Prevalence in Spain (2017–2028)
Figure 45: Secondary Osteoporosis Prevalence in Spain (2017–2028)
Figure 46: Osteoporotic Fractures Incidence in Spain (2017–2028)
Figure 47: Osteoporosis-related comorbidities in Spain (2017–2028)
Figure 48: Osteoporosis Prevalence in the United Kingdom (2017–2028)
Figure 49: Osteoporosis Diagnosed Prevalent Population in the United Kingdom (2017–2028)
Figure 50: Osteoporosis Gender-specific Prevalence in the United Kingdom (2017–2028)
Figure 51: Primary Osteoporosis Prevalence in the United Kingdom (2017–2028)
Figure 52: Secondary Osteoporosis Prevalence in the United Kingdom (2017–2028)
Figure 53: Osteoporotic Fractures Incidence in the United Kingdom (2017–2028)
Figure 54: Osteoporosis-related comorbidities in the United Kingdom (2017–2028)
Figure 55: Osteoporosis Prevalence in Japan (2017–2028)
Figure 56: Osteoporosis Diagnosed Prevalent Population in Japan (2017–2028)
Figure 57: Osteoporosis Gender-specific Prevalence in Japan (2017–2028)
Figure 58: Primary Osteoporosis Prevalence in Japan (2017–2028)
Figure 59: Secondary Osteoporosis Prevalence in Japan (2017–2028)
Figure 60: Osteoporotic Fractures Incidence in Japan (2017–2028)
Figure 61: Osteoporosis-related comorbidities in Japan (2017–2028)



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[骨粗鬆症の疫学予測(~2028)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆